by Kimberly Waller | Feb 27, 2026
The US Food and Drug Administration (FDA) has approved Desmoda (desmopressin acetate) oral solution for the management of arginine vasopressin deficiency (AVP-D). AVP-D is a rare neuroendocrine disorder caused by the loss or impaired function of vasopressinergic...
by Kimberly Waller | Jul 15, 2025
Takeda has announced positive data from two phase 3 clinical trials of oveporexton in patients with narcolepsy type 1 (NT1). NT1 is a rare, chronic neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. It is caused by reduced levels...
by Kimberly Waller | Nov 26, 2024
Anne Marie Morse, DO, of Geisinger Health, discusses the U.S. Food and Drug Administration (FDA) approval of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy ages 7 years and older. Narcolepsy is...
